Amgen

Moderna has launched an early trial of an Ebola mRNA vaccine. The article also mentions earnings reports from Amgen, Gilead Sciences, United Therapeutics, Novo, and Lilly.

Amgen has increased its full-year revenue forecast to $38.2 billion–$39.4 billion following a 10% rise in second-quarter revenue to $10.1 billion. The company also announced the discontinuation of a weight loss drug.

AstraZeneca's stock fell amid merger talks with Bristol Myers Squibb, which could create a $400 billion drugmaker, while Amgen disclosed a cybersecurity incident involving stolen patient data. Investors questioned the strategic need for the proposed merger, and Bristol Myers Squibb's shares rose in premarket trading.

Pharmaceutical company Amgen reported a data breach where threat actors stole corporate data and patient information stored in cloud systems operated by third-party service providers. The breach exposed patient health and proprietary information.

MrBeast and LeBron James are partnering to support 100 children with cancer through fundraising, awareness, and personalized experiences. The collaboration involves multiple organizations and includes events like meeting celebrities, attending screenings, and participating in blood drives.

The article highlights the top 10 Dow Jones Industrial Average stocks with the highest dividend yields, emphasizing their potential for reliable income and long-term growth. Examples include Nike (3.9%), Chevron (3.7%), and IBM (3.3%), with analysis on their financial stability and market positioning despite challenges like Nike's recent share decline.

An FDA advisory panel recommended allowing compounding pharmacies to manufacture peptides epitalon and semax but voted against emideltide. Amgen is challenging the FDA's proposal to withdraw its drug Tavneos from the U.S. market, citing new evidence from over 70 real-world studies.

The FDA approved Merck's Lipfendra, the first non-injectable pill targeting the PCSK9 protein to significantly reduce LDL cholesterol in high-risk patients. The drug offers a new option for those who need additional cholesterol-lowering beyond statins, with studies showing over 55% reductions in LDL levels.

The FDA approved Merck’s Lipfendra, the first non-injectable pill targeting PCSK9 to significantly reduce LDL cholesterol in patients not adequately controlled by statins. Clinical trials showed over 55% LDL reduction, and the drug was reviewed under the FDA's fast-track program.

The FDA approved Merck's Lipfendra, the first non-injectable pill to block PCSK9 and significantly reduce LDL cholesterol in high-risk patients. Clinical trials showed over 55% LDL reduction in six months, with minimal side effects, positioning it as an alternative to costly injectable PCSK9 inhibitors previously available from Amgen and others.

The FDA approved Merck's Lipfendra, the first non-injectable pill to significantly reduce LDL cholesterol in high-risk patients by blocking the PCSK9 protein. Clinical trials showed over 55% LDL reduction, and the drug was reviewed under an accelerated FDA program led by Dr. Marty Makary. It offers an alternative to costly injectable PCSK9 inhibitors previously available from Amgen and others.

Larry Gruber, a psoriatic arthritis patient, found his insurer Oscar HMO of Florida withheld a drug coupon meant to reduce his out-of-pocket costs, forcing him to pay $10,600 to meet his deductible. Insurers like Oscar Health use copay accumulator programs to retain pharmaceutical company discounts, which critics argue harms patients by making medications unaffordable and allows insurers to 'double-dip' on costs.

A Colorado judge suspended the state's price cap on the arthritis drug Enbrel, ruling it interferes with federal patent law. The cap, set at $31,000 annually, was blocked ahead of its 2027 implementation. Colorado's Prescription Drug Affordability Board, the first state entity to price-cap a drug, now faces legal uncertainty as Amgen challenges the policy.

A U.S. judge blocked Colorado from capping the price of Amgen's Enbrel, citing potential harm to the company, while a new Medicare program will offer obesity drugs at $50/month. Novo Nordisk and Eli Lilly's weight-loss treatments will be included in the trial.

The FDA has recalled nearly 1 million bottles of kidney and heart medications Corlanor (ivabradine) and Sensipar (cinacalcet) distributed by Amgen Inc. The recall for Corlanor is due to a foreign substance, while Sensipar's recall stems from CGMP deviations. The FDA noted the risk to patients is low.

Companies are launching numerous AI projects, but many lack strategic purpose or completion, leading to inefficiency. Executives from firms like West Monroe, Amgen, and Carvana warn that excessive AI initiatives can hinder progress and recommend prioritizing business-led transformations over technical focus.

GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are popular, prompting competitors like Pfizer and Amgen to develop similar products. The article discusses market competition and strategies by Novo Nordisk and Eli Lilly to maintain dominance in the weight loss drug sector.

A pharmaceutical company is challenging Colorado's first-in-the-nation price cap on a brand-name drug in court. Colorado's Prescription Drug Affordability Board (PDAB) set a cap on the drug Enbrel after determining it was unaffordable, prompting a lawsuit from Amgen. A judge is considering whether to issue a temporary injunction to block the cap while the case proceeds.

Peyton Greenside, CEO of BigHat Biosciences, critiques the hype around AI-driven drug development, emphasizing that while AI can rapidly design proteins, the actual drug-making process remains time-consuming and costly. The company, founded in 2019, partners with major pharmaceutical firms like Johnson & Johnson, Merck, and Amgen.